Xylyx Bio, a regenerative medicine company developing innovative solutions for tissue and organ repair, today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor...

  Award supports development of a pre-clinical cell-based assay platform to help scientists discover and test drug candidates for metastatic breast cancer